EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudie

Efficacy and Safety of Once‐Daily Prolonged‐Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double‐Blind, Active, and Placebo‐Controlled Trial

Shilpi Dhawan, Amol Bongirwar, Marta Muñoz-Tudurí iD, Aman Khanna Romesh, Prakash H Kurmi, Rahul Tulshidas Jankar

Pain Practice · 2025

DOI: 10.1111/papr.70061 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pain Practice, 2025. Verfasst von Shilpi Dhawan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Adalvo Limited, Bengaluru, India. Hauptthemen laut MEDLINE: Pregabalin, Diabetic Neuropathies, Analgesics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Adalvo Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare the efficacy and safety of a once‐daily prolonged release (PR) pregabalin formulation to pregabalin immediate release (IR) in patients with diabetic peripheral neuropathy (DPN). Patients and Methods This was a non‐inferiority, randomized, double‐blind, double‐dummy, multiple‐dose, multicenter, active and placebo controlled, three‐arm, parallel study. Patients were randomly assigned in a 1:1:1 ratio to receive pregabalin PR tablet, pregabalin IR hard capsule (Lyrica) or placebo at an optimized dose based on individual subject's response and tolerability for 13 weeks. The primary efficacy outcome was the change in the mean weekly pain score from baseline to end of treatment.

Results

Overall, 453 patients were randomized. In the per protocol (PP) analysis set, the least square mean (LSM) difference between test and reference treatment for the change in weekly pain score from baseline to end of treatment was 0.06 (95% CI: −0.28, 0.41, p = 0.7121), indicating that pregabalin PR was non‐inferior to pregabalin IR. In the Full Analysis Set (FAS), the LSM of change in mean weekly pain score from baseline to end of treatment for test, reference, and placebo groups were −3.43, −3.49, and −3.04, respectively. Test and reference products were superior to placebo ( p = 0.0158 and 0.0047, respectively).

Conclusion

The efficacy and safety of pregabalin PR was comparable to pregabalin IR for the treatment of pain in patients with DPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PregabalinDiabetic NeuropathiesAnalgesicsHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedTreatment OutcomeDelayed-Action PreparationsAdultPain Measurement

Stichwörter der Autor:innen

diabetic peripheral neuropathyneuropathic painpregabalin prolonged release

Substanzen

PregabalinAnalgesicsDelayed-Action Preparations

Autor:innen und Institutionen

  • Clinical Development, Adalvo Limited, Bengaluru, India.
  • BD&Innovation Department, Laboratorios Gebro Pharma S.A., Barcelona, Spain.
  • Aman Hospital and Research Center, Vadodara, India.
  • Shivam Hospital, Ahmedabad, India.
  • Asian Institute of Medical Science, Mumbai, India.

ORCID-Profile: Marta Muñoz-Tudurí

Förderung

  • Adalvo Limited

Zitieren

APA

Dhawan, S., Bongirwar, A., Muñoz-Tudurí, M., Romesh, A. K., Kurmi, P. H., & Jankar, R. T. (2025). Efficacy and Safety of Once‐Daily Prolonged‐Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double‐Blind, Active, and Placebo‐Controlled Trial. Pain Practice. https://doi.org/10.1111/papr.70061

Vancouver

Dhawan S, Bongirwar A, Muñoz-Tudurí M, Romesh AK, Kurmi PH, Jankar RT. Efficacy and Safety of Once‐Daily Prolonged‐Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double‐Blind, Active, and Placebo‐Controlled Trial. Pain Practice. 2025. doi:10.1111/papr.70061

BibTeX
@article{Dhawan2025,
  author = {Dhawan, Shilpi and Bongirwar, Amol and Muñoz-Tudurí, Marta and Romesh, Aman Khanna and Kurmi, Prakash H and Jankar, Rahul Tulshidas},
  title = {Efficacy and Safety of Once‐Daily Prolonged‐Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double‐Blind, Active, and Placebo‐Controlled Trial},
  journal = {Pain Practice},
  year = {2025},
  doi = {10.1111/papr.70061}
}
Kostenlos starten →